Board of Directors | Back to Overview

Dr. Garland has spent his career successfully bringing technological innovations to the marketplace. He holds a doctorate in biophysics from Stanford University, and served on the faculty of Stanford in the School of Engineering. He was co-founder of Cromemco, Inc. and served as president of the company for twelve years. During this time, Cromemco became a leading computer systems company, and a major supplier of computer graphics systems. Following the sale of Cromemco, Dr. Garland joined Canon as Vice President of Canon Research Center America, a position he held for eleven years. He is currently Chairman of Garland Actuarial LLC. He has written three books, and has been awarded 20 U.S. patents.

Dr. Melander focuses on defining small molecules that inhibit and disperse bacterial biofilms. He received his Ph.D. in organic chemistry from Columbia University in 1998, and then worked as a postdoctoral scholar at Caltech under the direction of Professor Peter Dervan from 1998-2001. From 2001-2002, Dr. Melander directed the organic synthesis department at Xencor, Inc. He returned to academic research as a Research Associate at The Scripps Research Institute in the Department of Molecular Biology in the laboratory of Professor Joel Gottesfeld. At Scripps, Dr. Melander utilized pyrrole/imidazole polyamides to treat colon cancer and Friedrich's ataxia. Dr. Melander is currently Associate Professor of Chemistry at North Carolina State University. Dr. Melander has received numerous awards, including an NIH Chemistry-Biology Research Training Grant and an NIH Postdoctoral Fellowship.

Dr. Cavanagh is the William Neal Reynolds Distinguished professor of Biochemistry at North Carolina State Unviersity. He is an expert in protein structural biology, particularly in how bacteria are able to protect themselves. Dr. Cavanagh received his Ph.D. in Chemistry/NMR spectroscopy from the University of Cambridge in 1988. He has held positions as a Senior Research Associate at The Scripps Research Institute, Director of Structural Biology at the Wadsworth Center (New York State Department of Health), Associate Professor of Biomedical Sciences (SUNY) and Professor of Chemistry (Purdue). Since 2000 he has been Professor of Biochemistry in the Department of Molecular & Structural Biochemistry at North Carolina State University. Dr. Cavanagh has served on numerous NIH and NSF grant review panels. He is author or co-author of over 90 peer-reviewed research publications and co-author of the well known and successful textbook "Protein NMR Spectroscopy." He has been awarded the Foulerton Gift & Binmore Kenner Fellowship of the Royal Society (1990), The Fullsome Award (1996) and NC State University Alumni Associations Outstanding Research Award (2005).

Mr. Culpepper is a proven leader in developing specialty products into best of class, growing, and sustainable businesses. He possesses the entrepreneurial spirit, corporate know-how, and strategic relationships required to successfully develop products. Mr. Culpepper is the Founder, President and CEO of SePRO Corporation, a leading specialty agrichemical company with offices in Carmel, IN and research facilities in Whitakers, NC. Prior to the formation of SePRO Corporation in 1994, he spent more than 25 years with Eli Lilly and DowElanco in a variety of sales, marketing and management roles. Mr. Culpepper is a co-founder and board member of several leading industry organizations, including Responsible Industry for Sound Environment (RISE), the Washington, D.C.-based trade association representing the specialty chemical industry; the RISE Aquatic Working Group; the Aquatic Ecosystem Restoration Foundation and is a board member of Crop Life America, another Washington, D.C.-based trade association representing the agrichemical industry. In addition to industry associations, Mr. Culpepper also serves on various community development boards including the BioCrossroads Advisory Board. BioCrossroads is a privately-funded organization that is dedicated to fully leveraging Indiana's existing world-class life science assets. Mr. Culpepper graduated from NC State in 1966 with a BS in Agronomy. He was a member of the NC State Campaign Steering Committee promoting the Achieve! Campaign, was named CALS Outstanding Alumnus for 2005, and recently completed his term as the first President of the North Carolina Ag Research Foundation.

Chief Technology Officer, China National Bluestar Corporation
Dr. Engelhardt studied chemistry at the University of Wuerzburg, Germany from 1979 to 1987 and holds a doctoral degree in physical chemistry. His graduate and post-graduate studies at various international research facilities focused on characterization of molecular liquids with X-ray, neutron and EXAFS spectroscopy. He started his career in 1987 as Process Development Chemist with Ciba-Geigy, and headed the department Process Development & Quality Assurance Ciba Grenzach in 1989. In 1993 he was appointed Head of Marketing & Business Development for Ciba Service Production, and after two years was promoted to Head of the Business Center Paper, located in Switzerland, with global responsibility for Fluorescent Whitening Agents. In 1999, he transferred to Japan as Head of Ciba's Consumer Care Division and Business Unit Home & Personal Care, North East Asia. In 2001 Dr. Engelhardt became Head of Technical Operations for Ciba's Segment Water & Paper Treatment, taking charge of a network of 13 production & formulation sites worldwide. In 2003 he was appointed Global Head of Process & Lubricant Additives as well as Head of Plastic Additives NAFTA, based in Tarrytown, US. In 2008 Thomas Engelhardt was appointed Head of Coating Effects Segment and member of the Executive Committee Ciba Specialty Chemicals. After BASF acquired Ciba, Dr. Engelhardt left the company and joined a major Chinese chemical corporation, China National Bluestar Corporation as Chief Technology Officer, based in Beijing. In 2010 he moved back to the US and took up a position as Senior Executive Advisor to a major international investment fund.

Mr. Stoneback’s diverse career brings a deep and broad base of business development experience to Agile Sciences. Having contributed to the success of several businesses in the start-up phase, as well as a few that required turnaround and/or repositioning; Keith has lead teams to compete and win in the healthcare services, medical device and hospital equipment space during the last 30 years. Throughout his career Mr. Stoneback has demonstrated a keen and intuitive focus on the customer, coupled with a relentless drive to define, validate and then consistently deliver the value proposition. Prior to joining Agile Sciences, Mr. Stoneback planned, organized and then implemented the US market launch of the unique and innovative patient monitoring product developed by Hoana Medical, the Hawaii-based medical device start-up. Prior to that assignment, Mr. Stoneback served as the president of the Health Management Services division of SHPS, an $85M/yr industry leader in providing disease management services to Fortune 1000 employers. Keith was promoted to that position after serving as the Chief Operating Officer for SHPS for several years. Prior to joining SHPS, he served as the CEO and/or president for several healthcare companies, including Surgical Laser Technologies (acquired by Photomedex) and AMSCO, a $300M/yr market leader in hospital decontamination systems. (AMSCO was acquired by Steris). At AMSCO, Keith served as the president of the Scientific Division and was a key member of the management team that took the company public in 1991, providing an 8X return for the private equity investors. Mr. Stoneback began his career with American Hospital Supply Corporation after graduating from Duke University in 1975.